Optic Nerve Disorders Drugs Market – Generate Massive Revenue in Upcoming Future 2021–2031 | SANTHERA PHARMACEUTICALS, Quark, Novartis AG

Posted on 2021-03-11 by Future Market Insights, Inc in Healthcare // 0 Comments

Optic nerve disorder, commonly known as optic neuropathy, is a medical condition indicating degeneration of the optic nerve. While mostly optic nerve disorders are hereditary, few of them are also acquired over the time. Some of probable etiologies (set of causes) leading to optic nerve disorders can include nutritional, ischemic, and toxic types. Patients suffering from optic nerve disorders show marked preferences for optic nerve disorders drugs over surgeries for treating optic neuropathies, as they are highly cost-effective and minimally risky.

Use of steroid-based optic nerve disorders drugs has been in practice, on account of their efficacy in easing the symptoms of optic nerve disorders. With the inflow of multiple drugs, patients are developing higher confidence on these optic nerve disorders drugs’ types and moving away from surgical interventions.

For detailed insights on enhancing your product footprint, request for a sample here@ https://www.factmr.com/connectus/sample?flag=S&rep_id=2689

Optic Nerve Disorders Drugs Market – Novel Developments

Some of the key market players operating in the optic nerve disorders drugs market include Novartis AG, Santhera Pharmaceuticals, Allergan plc., Stealth BioTherapeutics Inc., Quark, Takeda Pharmaceutical Company, Merck & Co., and others.

In 2019, Santhera Pharmaceuticals- a leading player in the optic nerve disorders drugs market- made an official announcement regarding its successful completion of patient enrollments in the on-going ‘Phase 1V’ study (LEROS) using Raxone® (idebenone) for treatment of hereditary optic neuropathies, otherwise known as optic nerve disorders. This 24- month long study was conducted across 31 study centers in the USA and Europe and the results are expected to be out by 2021.

In 2016, Quark Pharmaceuticals Inc. – a key player in the optic nerve disorders drugs market- partnered with Biocon Ltd., a leading biopharmaceutical firm to start various clinical trials of a drug meant to treat eye disorders. The study will further determine, over a duration of more than 12 months, the levels of efficacy and safety of drug candidate ‘;QPI-1007’ on the patients suffering from acute non-arteritic ischemic optic neuropathy (NAION), a medical condition wherein low blood supply to the optic nerves results in permanent vision impairment.

Optic Nerve Disorders Drugs Market- Dynamics

Optic Nerve Disorders Drugs Market – Pervasiveness of Optic Nerve Disorders Propels Growth

Rising number of instances of optic nerve disorders are indicating unabated demand for optic nerve disorders drugs in the coming years, thereby driving the optic nerve disorders drugs market. According to data by the World Health Organization (WHO), approx. 1.3 billion people suffer due to some sort of vision impairment. Among all the other possible causes, glaucoma (a condition leading to damage of optic nerves) has been identified as a prominent cause.

Rising demand for non-invasive procedures in the optometric space is also creating favorable grounds for optic nerve disorders drugs market. Patients, post realization of the risks and cost involved in surgical procedures, show high inclination toward optic nerve disorders drugs over surgeries, which is a key pacesetter of optic nerve disorders drugs market growth in the future.

To receive extensive list of important regions, ask for TOC here@ https://www.factmr.com/connectus/sample?flag=T&rep_id=2689

Optic Nerve Disorders Drugs Market: Segmentation

The optic nerve disorders drugs market is segmented on the basis of indication, drug class, end user and region.

Based on indication, the global optic nerve disorders drugs market is segmented into:

Ischemic Optic Neuropathies
Optic Neuritis and Perineuritis
Papilledema
Compressive Optic Neuropathies
Intrinsic Neoplasms
Hereditary Optic Neuropathies
Inflammatory Optic Neuropathies
Infectious Optic Neuropathies
Toxic and Nutritional Optic Neuropathies
Traumatic Optic Neuropathy
Glaucoma
Optic Disc Drusen
Anomalous Optic Neuropathy

Based on drug class, the global optic nerve disorders drugs market is segmented into:

Steroids
Nerve Tonics and Multivitamin
Analgesics
Anti-infective
Hyperosmotic Agents
Parasympathomimetics
Carbonic Anhydrase Inhibitors
Beta-blockers and Alpha-adrenergic Agonists
Others

Based on end user, the global optic nerve disorders drugs market is segmented into:

Hospitals
Clinics
Home Settings

Pre-Book Right Now for Exclusive Analyst Support @ https://www.factmr.com/checkout/2689/S

Optic Nerve Disorders Drugs Market: Key Players

Some of the major players in the global optic nerve disorders drugs market are SANTHERA PHARMACEUTICALS, Quark, Novartis AG, Allergan plc, Merck & Co., Stealth BioTherapeutics Inc., Takeda Pharmaceutical Company, and others.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.

Matched content

Editor’s pick